z-logo
open-access-imgOpen Access
Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis
Author(s) -
David Busquets,
Xavier Aldeguer
Publication year - 2012
Publication title -
journal of crohn s and colitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.277
H-Index - 80
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1016/j.crohns.2012.11.005
Subject(s) - medicine , adalimumab , ulcerative colitis , tumor necrosis factors , tumor necrosis factor alpha , gastroenterology , infliximab , disease
Dear Sir,Both medications and surgery have been used to treat ulcerative colitis (UC).1,2 Treatment with anti-TNF has shown to be effective in UC resistant to steroid or immunomodulator treatments.3 In this sense, the European Commission has recently approved adalimumab for the treatment of moderately to severely active UC in adult patients who have had an inadequate response to conventional therapy.We present a retrospective analysis of nine anti-TNF-naive patients with UC in whom adalimumab was administered as compassionate use …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom